Fidasimtamab - CAS 2377419-89-9

Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.

PD-1/PD-L1, HER, EGFR

Cell Cycle/Checkpoint, Apoptosis, Immunology/Inflammation, Angiogenesis, JAK/STAT signaling, Tyrosine Kinase/Adaptors

2377321

0.983

-20°C

Ice Packs

Inhibitory Antibodies